In Law360, Geoffrey Lin Discusses Growth in U.S. and China Life Sciences Licensing Deals

In The News
December 11, 2024
Attorneys:

Amid an increase in licensing deals between Chinese and U.S. biotechnology companies, Mandarin-speaking attorneys with deep experience in the health care and life sciences industries are in demand for the deals.

While language fluency is a useful skill to have as an attorney, so are a scientific background, understanding of the regulatory environment and extensive deals experience.

In a Law360 article, IP transactions partner Geoffrey Lin, who has been based in both Asia and the U.S., explained that the U.S. and China life sciences licensing trend is relatively new in the past two years. Geoffrey notes that if the biotechnology asset licensing trend continues, more law firms might seek and hire Mandarin-speaking health care and life sciences attorneys in the future.